Carboplatin

Warnings & Precautions

Carboplatin is a cytotoxic chemotherapeutic agent with dose-dependent bone marrow suppression as its primary toxicity. Careful patient selection, baseline diagnostics, and ongoing monitoring are essential to minimize complications in dogs and cats.

• Bone marrow suppression (dose-limiting toxicity): Neutropenia and thrombocytopenia are common and may be severe. Hematologic nadirs typically occur 14–21 days after administration. CBC monitoring before and after treatment is mandatory.
• Preexisting cytopenias or bleeding disorders: Contraindicated in patients with severe bone marrow depression, significant thrombocytopenia, or active bleeding.
• Hypersensitivity: Contraindicated in patients with a history of hypersensitivity to carboplatin or other platinum-containing compounds (e.g., cisplatin).
• Renal disease: Use cautiously in patients with renal insufficiency. Impaired renal function may reduce drug elimination and increase the risk of prolonged or severe myelosuppression, particularly in cats.
• Hepatic disease: Use cautiously in patients with preexisting hepatic dysfunction; dose adjustment and closer monitoring may be required.
• Active infection: Because of the risk of neutropenia, avoid or delay treatment in patients with uncontrolled infections.
• Small-breed dogs: Dogs weighing less than 15 kg are at increased risk for severe neutropenia and thrombocytopenia; dose reduction should be considered.
• Medication safety: Do not confuse CARBOplatin with CISplatin. Carboplatin is considered a high-alert medication and requires careful dose calculation and verification.
• Extravasation risk: Although classified as an irritant rather than a vesicant, tissue injury and necrosis have been reported with extravasation. Ensure proper IV catheter placement and monitor closely during administration.
• Aluminum incompatibility: Do not use needles or administration sets containing aluminum, as precipitation and loss of potency may occur.
• Hazardous drug handling: Classified as a hazardous drug. Appropriate personal protective equipment (PPE) and chemotherapy safety protocols must be used during preparation and administration.
• Reproductive safety: Carboplatin is embryotoxic and teratogenic. Confirm pregnancy status before administration in intact females. Use extreme caution in breeding animals.

Drug Interactions

Clinically relevant drug interactions with carboplatin are primarily related to additive myelosuppression, nephrotoxicity, or enhanced hematologic toxicity. Concurrent use does not always require absolute contraindication but warrants careful monitoring and dose adjustment.

• Myelosuppressive agents (e.g., other antineoplastics, immunosuppressants):
  Concurrent administration may result in additive or synergistic bone marrow suppression. Avoid combination when possible or intensify hematologic monitoring.
• Aminoglycosides (e.g., gentamicin):
  Increased risk of nephrotoxicity and potential ototoxicity when used together. Monitor renal function closely.
• Other nephrotoxic drugs:
  Concurrent use with nephrotoxic agents may potentiate renal injury and impair carboplatin elimination, increasing the risk of prolonged cytopenias.
• Radiation therapy:
  May increase hematologic toxicity when administered concurrently. Adjust protocol and monitor CBC closely.
• Live and inactivated vaccines:
  Myelosuppressive therapy may reduce vaccine efficacy and increase the risk of adverse effects. Vaccination should be carefully timed relative to chemotherapy cycles.
• Tigilanol tiglate:
  Treatment protocols generally do not permit concurrent use with other antineoplastic drugs; combination should be avoided.

Side Effects & Overdose

Side Effects

Adverse effects of carboplatin in dogs and cats are primarily dose-dependent and related to bone marrow suppression. Most non-hematologic effects are gastrointestinal and typically self-limiting.

• Bone marrow suppression (dose-limiting toxicity):
  Neutropenia and thrombocytopenia are the most common adverse effects. Hematologic nadirs usually occur 14–21 days after administration. Severe cytopenias may predispose to infection or bleeding.
• Gastrointestinal effects:
  Vomiting, diarrhea, and inappetence may occur, typically within 2–5 days after treatment. These effects are generally milder than those associated with cisplatin.
• Infection and hemorrhage:
  Secondary to neutropenia or thrombocytopenia; monitor for fever, lethargy, petechiae, ecchymoses, or abnormal bleeding.
• Renal toxicity:
  Less common and generally less severe than with cisplatin, but may occur, especially when combined with other nephrotoxic agents.
• Hepatic enzyme elevations:
  Mild increases in liver enzymes may be observed; clinically significant hepatotoxicity is uncommon.
• Hypersensitivity reactions:
  Rare but possible; delayed cutaneous reactions and anaphylactoid-type responses have been reported.
• Extravasation injury:
  Although classified as an irritant, tissue necrosis has been reported following accidental perivascular administration.
• Coat changes:
  Mild hair coat changes may occur; breeds with continuously growing hair coats may be more prone to alopecia.

Overdose

There is no specific antidote for carboplatin overdose. Toxicity is expected to be an extension of its pharmacologic effects, primarily severe and prolonged bone marrow suppression.

• Severe myelosuppression:
  Marked neutropenia and thrombocytopenia with increased risk of sepsis or life-threatening hemorrhage.
• Hepatic and renal toxicity:
  May occur at supratherapeutic doses, particularly in patients with preexisting organ dysfunction.
• Neurologic or ototoxic effects:
  Rare but possible at high cumulative exposures.
• Management:
  Treatment is supportive and includes intensive monitoring, broad-spectrum antimicrobials for febrile neutropenia, IV fluid therapy, transfusion support if indicated, and organ function monitoring.

Key Notes

Practical clinical considerations to optimize the safe and effective use of carboplatin in dogs and cats:

• Dose calculation accuracy:
  Carboplatin is dosed based on body surface area (mg/m²) in most oncology protocols. Accurate weight measurement and correct BSA calculation are essential to prevent underdosing or life-threatening toxicity.
• IV administration technique:
  Administer via a well-placed, patent intravenous catheter over approximately 15 minutes. Flush the catheter before and after infusion to reduce the risk of local irritation.
• Treatment interval planning:
  Standard dosing intervals are typically every 3 weeks, but adjustments may be required based on individual patient tolerance and protocol design.
• Combination protocols:
  When incorporated into multidrug chemotherapy plans, sequencing and scheduling must follow established oncology protocols to optimize efficacy and minimize cumulative toxicity.
• Tumor response assessment:
  Objective measurement of tumor size (physical exam or imaging) should be performed at regular intervals to determine treatment response and guide continuation decisions.
• Client safety counseling:
  Owners should wear disposable gloves when handling urine, feces, or vomit for several days after treatment, as drug metabolites may be present in excreta.
• Hospital handling protocols:
  Preparation should occur in a designated chemotherapy area using appropriate safety equipment, and all materials must be disposed of according to hazardous waste guidelines.
• Expectation management:
  The goal of veterinary chemotherapy is typically improved quality of life and tumor control rather than cure; clear communication with owners is essential before initiating treatment.